Drug Trial Radar · NCT03658070
A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours
Last checked: Nov 19, 2026Latest source record: Aug 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
34
Planned (sponsor's estimate)
Start
Dec 19, 2018
Primary completion
Dec 2020
Study completion Dec 2020
Sponsor
- Lead sponsor
- Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Tigermed Consulting Co., Ltd
- First posted
- Sep 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. To observe the safety and tolerability of oral XY0206 in patients with advanced/metastatic malignant solid tumor in China, and observe the drug dose limiting toxicity (DLT) to establish the maximum tolerated dose (MTD) in humans. 2. To investigate the pharmacokinetic (PK) characteristics, pharmacodynamics (PD) characteristics, and PK/PD correlation of single and multiple doses of XY0206 in patients with advanced/metastatic malignant solid tumors to provide dose selection basis for clinical studies; 3. To evaluate the effect of standard meal on main PK parameters of XY0206; 4. To determine the metabolites of XY0206 in patients with advanced/metastatic malignant solid tumor. 5. To explore the correlation between PK and QTcF. 6. Preliminary investigates the effectiveness of XY0206 in patients with advanced/metastatic malignant solid tumors.
Conditions
- Advanced or Metastatic Solid Tumours
Interventions
XY0206Drug
Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- AETime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- ADRTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- SAETime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Blood routineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Urine routineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Stool routineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Blood biochemistryTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Coagulation functionTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- 12 lead ecgTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Body temperatureTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Blood pressureTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Heart rateTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- BreathingTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- General conditionTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- SkinTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- HeadTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- EyesTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- EarsTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- NoseTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- ThroatTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- HeartTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- LungTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- ChestTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- AbdomenTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- LimbsTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- NervesTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Back/spineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Lymph nodesTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Hainan Medical College
Haikou, Hainan, China · Not yet recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Not yet recruiting
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.